549 related articles for article (PubMed ID: 19846029)
1. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
Bagust A; Greenhalgh J; Boland A; Fleeman N; McLeod C; Dickson R; Dundar Y; Proudlove C; Shaw R
Pharmacoeconomics; 2010; 28(6):439-48. PubMed ID: 20465313
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib for the treatment of relapsed non-small cell lung cancer.
McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
14. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the treatment of rheumatoid arthritis.
Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
[TBL] [Abstract][Full Text] [Related]
19. Telbivudine for the treatment of chronic hepatitis B infection.
Hartwell D; Jones J; Harris P; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
[TBL] [Abstract][Full Text] [Related]
20. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
